# Innoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company Progress
Canonical URL: https://biopharmsignal.com/news/INVA/innoviva-reports-first-quarter-2026-financial-results-highlights-recent-company-progress
Ticker: INVA
Company: Innoviva
Source: Innoviva
Published: 2026-05-06 20:05 EST
Original Source URL: https://investor.inva.com
## Summary

Generated $58.6 million in revenue from resilient royalties portfolio Achieved IST U.S. net product sales of $34.2 million for the first quarter, representing 29% year-over-year growth Significant value created across strategic healthcare asset portfolio BURLINGAME, Calif.

## Article Body
Generated $58.6 million in revenue from resilient royalties portfolio Achieved IST U.S. net product sales of $34.2 million for the first quarter, representing 29% year-over-year growth Significant value created across strategic healthcare asset portfolio BURLINGAME, Calif.
## Recent Company News
- 2026-05-06 20:05 EST — [Innoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company Progress](https://biopharmsignal.com/news/INVA/innoviva-reports-first-quarter-2026-financial-results-highlights-recent-company-progress) — Source: Innoviva
- 2026-02-25 21:05 EST — [Innoviva Reports Fourth Quarter and Full Year 2025 Financial Results; Highlights Recent Company Progress](https://biopharmsignal.com/news/INVA/innoviva-reports-fourth-quarter-and-full-year-2025-financial-results-highlights-recent-company-progress) — Source: Innoviva
- 2026-02-19 13:00 EST — [Innoviva to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference](https://biopharmsignal.com/news/INVA/innoviva-to-participate-in-the-oppenheimer-36th-annual-healthcare-life-sciences-conference) — Source: Innoviva
- 2025-12-12 21:56 EST — [U.S. FDA Approves NUZOLVENCE® (zoliflodacin), a First-in-Class, Single-dose, Oral Antibiotic for the Treatment of Uncomplicated Urogenital Gonorrhea in Adults and Adolescents](https://biopharmsignal.com/news/INVA/u-s-fda-approves-nuzolvencer-zoliflodacin-a-first-in-class-single-dose-oral-antibiotic-for-the-treatment-of-uncomplicated-urogenital-gonorrhea-in-adults-and-adolescents) — Source: Innoviva
- 2025-12-11 23:35 EST — [Innoviva Specialty Therapeutics Announces Publication in The Lancet of Positive Zoliflodacin Phase 3 Data for the Treatment of Uncomplicated Urogenital Gonorrhea](https://biopharmsignal.com/news/INVA/innoviva-specialty-therapeutics-announces-publication-in-the-lancet-of-positive-zoliflodacin-phase-3-data-for-the-treatment-of-uncomplicated-urogenital-gonorrhea) — Source: Innoviva
## Related News
- 2026-07-21 20:15 EST — BFRG — [BullFrog AI to Participate in Water Tower Research Fireside Chat on Thursday, July 23, 2026](https://biopharmsignal.com/news/BFRG/bullfrog-ai-to-participate-in-water-tower-research-fireside-chat-on-thursday-jul-78357ce8)
- 2026-07-21 20:05 EST — CLPT — [ClearPoint Neuro to Announce Second Quarter 2026 Results August 3, 2026](https://biopharmsignal.com/news/CLPT/clearpoint-neuro-to-announce-second-quarter-2026-results-august-3-2026-6e4f3c05)
- 2026-07-21 20:05 EST — TCMD — [Tactile Medical to Release Second Quarter of Fiscal Year 2026 Financial Results on August 10, 2026](https://biopharmsignal.com/news/TCMD/tactile-medical-to-release-second-quarter-of-fiscal-year-2026-financial-results--798d4004)
- 2026-07-21 20:05 EST — PIII — [P3 Health Partners Schedules Second Quarter 2026 Earnings Release and Conference Call](https://biopharmsignal.com/news/PIII/p3-health-partners-schedules-second-quarter-2026-earnings-release-and-conference-6c9bd8a7)
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)